Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
[2.]
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, et al.
Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
J Am Coll Cardiol, 44 (2004), pp. 720-732
[3.]
J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, J.H. Stein, et al.
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
J Am Coll Cardiol, 51 (2008), pp. 1512-1524
[4.]
G. Assmann, P. Cullen, J.C. Fruchart, H. Greten, M. Naruszewicz, A. Olsson, et al.
International Task Force for Prevention of Coronary Heart Disease. Implications of emerging risk factors for therapeutic intervention.
Nutr Metab Cardiovasc Dis, 15 (2005), pp. 373-381
[5.]
A.J. Szalai.
The biological functions of C-reactive protein.
Vascul Pharmacol, 39 (2002), pp. 105-107
[6.]
I. Jialal, S. Devaraj, S. Venugopal.
C-reactive protein: risk marker or mediator in atherothrombosis?.
Hypertension, 44 (2004), pp. 6-11
[7.]
J.L. Sepúlveda, J.L. Mehta.
C-reactive protein and cardiovascular disease: a critical appraisal.
Curr Opin Cardiol, 20 (2005), pp. 407-416
[8.]
P.M. Ridker, N.J. Brown, D.E. Vaughan, D.G. Harrison, J.L. Mehta.
Established and emerging plasma biomarkers in the prediction of first atherothrombotic events.
Circulation, 109 (2004),
[9.]
S.K. Singh, M.V. Suresh, B. Voleti, A. Agrawal.
The connection between C-reactive protein and atherosclerosis.
Ann Med, 40 (2008), pp. 110-120
[10.]
S. Devaraj, U. Singh, I. Jialal.
The evolving role of C-reactive protein in atherothrombosis.
Clin Chem, 55 (2009), pp. 229-238
[11.]
K. Musunuru, B.G. Kral, R.S. Blumenthal, V. Fuster, C.Y. Campbell, T.J. Gluckman, et al.
The use of high-sensitivity assays for C-reactive protein in clinical practice.
Nat Clin Pract Cardiovasc Med, 5 (2008), pp. 621-635
[12.]
S. Erqou, S. Kaptoge, P.L. Perry, E. Di Angelantonio, A. Thompson, I.R. White, et al.
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Emerging Risk Factors Collaboration.
JAMA, 302 (2009), pp. 412-423
[13.]
S. Tsimikas, E.S. Brilakis, E.R. Miller, J.P. McConnell, R.J. Lennon, K.S. Kornman, et al.
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
N Engl J Med, 353 (2005), pp. 46-57
[14.]
P.R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, B.G. Nordestgaard.
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.
Circulation, 117 (2008), pp. 176-184
[15.]
F. Kronenberg, A. Steinmetz, G.M. Kostner, H. Dieplinger.
Lipoprotein(a) in health and disease.
Crit Rev Clin Lab Sci, 33 (1996), pp. 495-543
[16.]
L.L. Humphrey, R. Fu, K. Rogers, M. Freeman, M. Helfand.
Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis.
Mayo Clin Proc, 83 (2008), pp. 1203-1212
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.